2. Alexis A.F., Blackcloud P. Psoriasis in Skin of Color: Epidemiology, Genetics, Clinical Presentation and Treatment Nuances. J. Clin. Aesthet. Dermatol. 2014; 7(11): 16–24.

3. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch. Dermatol. 2005; 141(12): 1537–41.

4. Tollefson M.M., Crowson C.S., McEvoy M.T., Kremers M.H. Incidence of psoriasis inchildren: a population-based study. J. Am. Acad. Dermatol. 2010; 62(6): 979–87. DOI:10.1016/j.jaad.2009.07.029

5. Yeung H., Wan J., Van Voorhees A.S., Callis Duffin K., Krueger G.G., Kalb R.E. et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate-to-severe psoriasis. J. Am. Acad. Dermatol. 2013; 68(1): 64–72. DOI: 10.1016/j.jaad.2012.06.035

6. Galezowski A., Maccari F., Hadj-Rabia S., Sigal M.L., Phan A., Lahfa M. et al. le GEM Resopso et le Groupe de recherche de la Société française de dermatologie pédiatrique. Psoriatic arthritis in France, from infants to the elderly: Findings from two cross-sectional, multicenter studies. Ann. Dermatol. Venereol. 2017; Nov 13. pii: S0151-9638(17)30968-7.

7. Egeberg A., Kristensen L.E., Thyssen J.P., Gislason G.H., Gottlieb A.B., Coates L.C. et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann. Rheum. Dis. 2017; 76(9):1 591–7. DOI: 10.1136/annrheumdis-2016-210963

8. Zenke Y., Ohara Y., Kobayashi D., Arai S., Kishimoto M., Okada M. et al. Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves. J. Am. Acad. Dermatol. 2017; 77(5): 863–7. DOI: 10.1016/j.jaad.2017.04.001.

9. Naldi L., Mercury S.R. Epidemiology of comorbidities in psoriasis. Dermatol. Ther. 2010; 23: 114–8. DOI:10.1111/j.1529-8019.2010.01304

10. Goulding J.M., Price C.L., Defty C.L., Hulangamuwa C.S., Bader E., Ahmed I. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br. J. Dermatol. 2011; 164: 103–9.

11. Leal L., Ribera M., Daudén E. Psoriasis and HIV infection. Actas Dermo-Sifiliográficas 2008; 99(10): 753–63.

12. Morar N., Willis-Owen S.A., Maurer T., Bunker C.B. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect. Dis. 2010; 10(7): 470–8.

13. Бакулев А.Л., Знаменская Л.Ф., Хобейш М.М., Олисова О.Ю. Федеральные клинические рекомендации по ведению больных псориазом. М., 2013. URL: http://rykovodstvo.ru/exspl/48501/index. html

14. Capon F. The Genetic Basis of Psoriasis. International Journal of Molecular Sciences 2017; 18(12): 2526. DOI: 10.3390/ijms18122526.

15. Gervin K., Vigeland M.D., Mattingsdal M., Hammerø M., Nygаrd H., Olsen A.O. et al. DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genetics 2012; 8(1): e1002454. http://dx.doi.org/10.1371/journal.pgen.1002454

16. Chen H., Hayashi G., Lai O.Y., Dilthey A., Kuebler P.J., Wong T.V. et al. Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genet. 2012; 8(2): e1002514. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3343879/

17. Chandra A., Lahiri A., Senapati S., Basu B., Ghosh S., Mukhopadhyay I. et al. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population. Int. J. Sci. Reports. Published online 2016 Apr 6. DOI: 10.1038/srep24059.

18. Ogdie A., Gelfand J.M. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr. Rheumatol Rep. 2015; 17(10): 64. DOI: 10.1007/s11926-015-0540-1

19. Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017; 49: 1–8. DOI: 10.1016/j.coi.2017.07.007

20. Tokura Y., Mori T., Hino R. Psoriasis and other Th17-mediated skin diseases. J. UOEH. 2010; 32(4): 317–28.

21. Johnston A., Xing X., Wolterink L., Barnes D.H., Yin Z., Reingold L. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 2017; 140(1): 109–20.

22. Hawkes J.E., Nguyen G.H., Fujita M., Florell S.R., Callis D.K., Krueger G.G., O’Connell R.M. microRNAs in Psoriasis. J. Invest. Dermatol. 2016; 136(2): 365–71. https://www.ncbi.nlm.nih.gov/pubmed/26802234.

23. Jaehwan Kim, Pranay Nadella, Dong Joo Kim, Carrie Brodmerkel, Joel Correa da Rosa, James G. Krueger. Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. PLoS One 2015; 10(7): e0132454. DOI: 10.1371/journal.pone.0132454.

24. Seneschal J., Clark R.A., Gehad A., Baecher-Allan C.M., Kupper T.S. Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity 2012; 36(5): 873–84.

25. Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of Psoriasis. Ann. Rev. Immunol. 2014; 32: 227–55. DOI: 10.1146/annurev-immunol-032713-120225.

26. Klatt N.R., Funderburg N.T., Brenchley J.M. Microbial translocation, immune activation, and HIV disease. Trends in Microbiology 2013; 21: 6–13.

27. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485–98.

28. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J..et al. IL-17-producing CD8+ T- lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009; 86: 435–43.

29. Nagendran Prabhakaran, Telanseri J. Jaisankar, Abdoul Hamide, Munisamy Malathi, Rashmi Kumari, Devinder Mohan Thappa. Effect of antiretroviral therapy on mucocutaneous manifestations among Human Immunodeficiency Virus-infected patients in a tertiary care centre in South India. Indian Journal of Sexually Transmitted Diseases and AIDS 2015; 36(2): 166–73.

30. Aditi Chandra, Swapan Senapati, Sudipta Roy, Gobinda Chatterjee, Raghunath Chatterjee. Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin. Epigenetics 2018; 10: 108. https://doi.org/10.1186/s13148-018-0541-9

31. Sonkoly E., Wei T., Janson P.C., Saaf A., Lundeberg L., Tengvall-Linder M., Norstedt G., Alenius H., Homey B., Scheynius A., Stahle M., Pivarcsi A. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007; (2): e610.

32. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 2003; (4): 540–5.

33. Baliwag J., Barnes D.H., Johnston A. Cytokines in psoriasis. Cytokine 2015; 73(2): 342–50. DOI: 10.1016/j.cyto.2014.12.014

34. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I. et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Brit. J. Dermatol. 2008; 159: 1086–91.

35. Iketleng T., Moyo В., Gaseitsiwe S., Nyombi B., Mitchell R.M., Makhema J. et al. Plasma Cytokine Levels in Chronic Asymptomatic HIV-1 Subtype C Infection as an Indicator of Disease Progression in Botswana: A Retrospective Case Control Study. AIDS Res. Hum. Retroviruses 2016; 32(4): 364–9. DOI: 10.1089/AID.2015.0163.

36. Guo H., Gao J., Taxman D.J., Ting J.P.Y., Su L. HIV-1 Infection Induces Interleukin-1β Production via TLR8 Protein-dependent and NLRP3 Inflammasome Mechanisms in Human Monocytes. J. Biol. Chem. 2014; 289; 21716–26. DOI: 10.1074/jbc.M114.566620.

37. Kimball A.B., Gladman D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J. et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 2008; 58: 1031–42.

38. Jost M., Kari C., Rodeck U. The EGF receptor – an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 2000; 10(7): 505–10.

39. Адаскевич В.П. Диагностические индексы в дерматологии. М.: Издательство Панфилова; БИНОМ. Лаборатория знаний, 2014. 352 с. URL: http://binom-press.ru/books_1/dermat/diagn_ind_dermat_cont.pdf

40. Morar N., Dlova N. C., Mosam A., Aboobaker J. Cutaneous manifestations of HIV in Kwa-Zulu Natal, South Africa . Int. J. Dermatol. 2006; 45(8); 1006 – 7.

41. Олейник А.Ф., Фазылов В.Х. Причины иммунологической неэффективности антиретровирусной терапии пациентов с ВИЧ-инфекцией. Казанский медицинский журнал 2014; 95(4): 581–8.

42. Kurd S.K., Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003–2004. J. Am. Acad. Dermatol. 2009; 60(2): 218–24.

43. Кацамбас Ф.Д., Лотти Т.М. Европейское руководство по лечению дерматологических заболеваний. Пер. с англ. М: МЕДпресс-информ, 2014; 392–406.

44. Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E.M., Nast A., Franke J. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch. Dermatol. Res. 2011; 303(1): 1–10.

45. Papp K., Reich K., Leonardi C.L., Kircik L., Chimenti S., Langley R.G. et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis

Для цитирования: Евдокимов Е.Ю., Сундуков А.В., Горелова Е.А. Иммунологические и клинические особенности псориаза у ВИЧ-инфицированных больных. Эпидемиол. инфекц. болезни. Актуал. вопр. 2018; (4):82–91